#ESC26: AstraZeneca's relaxin pill shows promise in mid-stage heart failure trial

MUNICH — AstraZeneca’s oral relaxin agonist was able to improve cardiac function in some, though not all, patients in a mid-stage trial. While the study was only a partial success, this is still a decent showing ...